SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly
✍️ Advertorial Desk, .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow, Class, Wp-Block-Co-Authors-Plus, Display Inline, .Wp-Block-Co-Authors-Plus-Avatar, Where Img, Height Auto Max-Width, Vertical-Align Bottom .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow .Wp-Block-Co-Authors-Plus-Avatar, Vertical-Align Middle .Wp-Block-Co-Authors-Plus-Avatar Is .Alignleft .Alignright📅 November 08, 2025 12:00 AM🕐 Scraped: November 09, 2025
Summary: -Companies will collaborate on RNAi research for metabolic disease targets BOSTON, Nov. 8, 2025 /PRNewswire/ — SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and Company (“Lilly”). The companies will collaborate to advance RNAi candidates for metabolic diseases, based on SanegeneBio’s proprietary tissue selective […]
-Companies will collaborate on RNAi research for metabolic disease targets
BOSTON, Nov. 8, 2025 /PRNewswire/ — SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and Company (“Lilly”). The companies will collaborate to advance RNAi candidates for metabolic diseases, based on SanegeneBio’s
📰
Continue Reading on Laotian Times
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.
